split-banner-image

Neo-N

Closed

BCT 1902: Neo-N

BCT Study Chair:

Sherene Loi

The Neo-N clinical trial will investigate if using an immunotherapy drug together with chemotherapy, is safe and effective in treating breast cancer before surgery in women and men with early triple negative breast cancer.

international

1 (Italy)

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

110

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

18

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

Neo-N PUBLICATIONS

2023

Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer (TNBC): (BCT1902/IBCSG 61-20 Neo-N).

Zdenkowski N, Loi S, Niman S, Francis P, Baron Hay S, Fox W, Punie K, Menzies A, Angus R, Mavin C, Rennie L, Stoodley I, Mann B, Kuper-Hommel M, Regan M. SABCS 2023; LBO-03, Presentation

Institutions

YOUR DONATION CAN HELP PROLONG A LIFE

Make a gift now